Revelation Biosciences (NASDAQ:REVB) Trading 1.4% Higher – Time to Buy?

Revelation Biosciences, Inc. (NASDAQ:REVB) rose 1.4% during mid-day trading on Wednesday . The company traded as high as $1.04 and last traded at $1.00. Approximately 17,999 shares traded hands during mid-day trading, a decline of 58% from the average daily volume of 42,725 shares. The stock had previously closed at $0.9866.

Wall Street Analyst Weigh In

Separately, Weiss Ratings cut shares of Revelation Biosciences from a “sell (e+)” rating to a “sell (e)” rating in a report on Tuesday, August 25th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.

Revelation Biosciences Trading Up 1.0%

The firm has a market cap of $4.02 million, a price-to-earnings ratio of -0.08 and a beta of -0.14. The firm has a 50-day moving average of $1.06 and a two-hundred day moving average of $1.12.

Revelation Biosciences (NASDAQ:REVB) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.87) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.88) by $0.01. As a group, equities analysts anticipate that Revelation Biosciences, Inc. will post -5.18 EPS for the current year.

Hedge Funds Weigh In On Revelation Biosciences

Hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC acquired a new stake in shares of Revelation Biosciences in the 4th quarter valued at $27,000. Armistice Capital LLC bought a new position in Revelation Biosciences in the 3rd quarter valued at $114,000. Finally, Sabby Management LLC increased its stake in shares of Revelation Biosciences by 192.5% in the fourth quarter. Sabby Management LLC now owns 605,702 shares of the company’s stock valued at $484,000 after buying an additional 398,651 shares in the last quarter. 12.80% of the stock is owned by institutional investors and hedge funds.

About Revelation Biosciences

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.